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Longer-Term Therapy for Symptoms Attributed to Lyme Disease
To the Editor: In the placebo-controlled trial by 
Berende et al. (March 31 issue)1 involving patients 
with persistent symptoms attributed to Lyme dis-
ease, all the patients received an initial 2-week 
course of intravenous ceftriaxone. Among the 
patients who subsequently received placebo, was 
the 12.6% reduction from baseline in the fatigue 
score the result of the initial 2-week course of 
ceftriaxone? The results from other studies that 
have involved patients with post-treatment symp-
toms of Lyme disease may help answer this ques-
tion. In two separate studies, the effect of an 
intravenous placebo on fatigue was assessed over 
a 6-month period with the use of an 11-item 
fatigue-severity scale. In one study, a 9.1% reduc-
tion from baseline in the fatigue score was ob-
served in the placebo group,2 and in the second 
study, a 14.5% reduction from baseline was ob-
served in the placebo group.3 Thus, the fact that 
the magnitude of reduction in fatigue score 
among the participants who were given placebo 
in other studies of post-treatment Lyme disease 
symptoms was similar to that observed in the 
trial by Berende et al.1 suggests that the 2-week 
course of ceftriaxone in this trial probably pro-
vided no therapeutic benefit with respect to 
 fatigue.
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To the Editor: The trial by Berende et al. ad-
dresses an often-discussed issue regarding longer 
treatment duration for persistent symptoms at-
tributed to Lyme disease. Although the inclusion 
criteria and the design of the study reflect clini-
cal practice and the results are valuable for dis-
couraging unneeded longer-term antibiotic treat-
ment, we would like to highlight an important 
limitation. The diagnosis of Lyme disease in pa-
tients who do not have the classic clinical mani-
festations is challenging and prone to error.1 In 
this trial, a considerable percentage of patients, 
in particular patients who had nonspecific symp-
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toms and only IgM antibodies, may not have had 
Lyme disease. The median duration of symptoms 
was more than 2 years, and therefore positive 
IgG antibodies, not IgM antibodies, are required 
to confirm Lyme disease. A total of 22 to 36% of 
the patients received a diagnosis of Lyme disease 
on the basis of positive IgM antibodies, and these 
patients probably did not benefit from any anti-
biotic treatment because they had received a mis-
diagnosis. The inclusion of these patients may 
have blurred a possible difference between the 
placebo group and the two antibiotic treatment 
groups, although in our experience as well, longer 
treatment duration does not have an effect on the 
severity of symptoms.
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The authors reply: We agree with Wormser 
that any effects observed during the follow-up of 
our patient groups cannot be attributed to ceftri-
axone, as was discussed in our article. Our trial 
was designed to compare longer-term therapy 
with shorter-term therapy and does not allow for 
any conclusions to be made on the potential ef-
fects of the standardized pretreatment with ceftri-
axone in all randomized study groups. As Worm-
ser suggests, the reported changes in outcomes, 
including fatigue severity, may be ascribed to 
placebo effects. Responses to placebo are known 
to contribute to beneficial outcomes in clinical 
trials, as has been shown for a broad variety of 
symptoms, including fatigue, and for physiologi-
cal responses, such as behaviorally conditioned 
suppression of markers of infection and immu-
nity.1 Placebo effects are based on the expecta-
tions of patients and care professionals regard-
ing the benefits of treatment. These expectations 
are shaped by a combination of conscious and 
automatic learning processes, such as condition-
ing by drug use and patient–physician interac-
tions. Investigators in future trials may disen-
tangle these effects by using more sophisticated 
research designs to allow comparisons with the 
natural course of disease (without any placebo 
effects) and open-label conditions (to maximize 
beneficial placebo responses).1
Erb et al. suggest that patients with Borrelia 
burgdorferi IgM antibodies may not have had Lyme 
disease. However, IgM antibodies are known to 
persist for up to 3 years after infection,2,3 and 
false positive IgM immunoblot results occurred 
in fewer than 10% of healthy controls in a recent 
study.4 Our inclusion criteria aimed at selecting 
patients who did not have proof of active Lyme 
disease at baseline but who had been infected by 
B. burgdorferi previously. Patients had to have ei-
ther documented, proven Lyme disease diagnosed 
a maximum of 4 months before the onset of 
symptoms or serologic proof of prior infection, 
as confirmed by immunoblot assay. Only 25 
patients (9%) were included in the trial solely on 
the basis of positive IgM immunoblot assay re-
sults as a marker of prior infection. Among 
those patients, the physical-component summary 
score of the RAND-36 Health Status Inventory at 
the end of therapy was similar to that of patients 
who were negative for IgM antibodies and did 
not differ significantly among the study groups. 
Sensitivity analyses that excluded patients who 
were positive for IgM antibodies yielded results 
similar to those of the main analyses. Thus, the 
assumptions by Erb et al. are unwarranted.
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